Affect in Parkinson's disease: validation of the two-factor approach
Identifieur interne : 000520 ( PascalFrancis/Checkpoint ); précédent : 000519; suivant : 000521Affect in Parkinson's disease: validation of the two-factor approach
Auteurs : Emmanuelle Pourcher [Canada, France] ; Sophie Remillard [Canada] ; Henri Cohen [Canada, France]Source :
- Journal of the neurological sciences [ 0022-510X ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Depression in Idiopathic Parkinson's disease (IPD) is frequent, difficult to recognize, under managed and has a profound impact on quality of life. Current categorization of diagnosis in psychiatry poorly applies to the protean manifestations of mood disorders presented by parkinsonian patients. In this study we have chosen to dissect the state of depressive mood as assessed with the Beck Depression Inventory (BDI) at different points in time of pharmacological interventions using a dimensional approach. The 21 items of the BDI were classified in two new categories or factors: hyperkinetic and hypokinefic. The hyperkinetic factor included all items related to unbalanced intrusions of negative feelings and ideas, as well as to behavioral hyperactivity. The hypokinetic factor included all items related to loss of drive for appetitive behaviors and loss of mental and physical energy. The objectives were to (1) compare different pharmacological treatments on the two-factor approach in PD depression, (2) determine the influence of levodopa therapy on the two-factor approach, and (3) explore the two-factor approach in placebo conditions. Three sets of analyses using the hypo/hyperkinetic dichotomy favour a neurobiological dissociation of these factors in response to pharmacological intervention: symptoms of the hyperkinetic factor are responsive to serotonergic drugs while those of the hypokinetic one are not and may even show deterioration under SSRIs. In contrast, the hypokinetic factor is responsive to dopaminergic drugs and may show deterioration under serotonergic drugs. Furthermore, the two factors seem to transiently dissociate on placebo intervention aiming at correcting either mood or motor status. The dimensional approach to depression symptomatology may thus be of heuristic value in probing aminergic modulation of mood in IPD and establishing new correlations between affective and motor symptoms.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:10-0131705Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Affect in Parkinson's disease: validation of the two-factor approach</title><author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Psychology and Cognitive Neuroscience Laboratory, Université Paris Descartes - CNRS (UMR-8189)</s1><s2>Boulogne-Billancourt</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Boulogne-Billancourt</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre de Recherche Université Laval Robert-Giffard</s1><s2>Beauport</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Centre de Recherche Université Laval Robert-Giffard</wicri:noRegion></affiliation></author><author><name sortKey="Remillard, Sophie" sort="Remillard, Sophie" uniqKey="Remillard S" first="Sophie" last="Remillard">Sophie Remillard</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Cohen, Henri" sort="Cohen, Henri" uniqKey="Cohen H" first="Henri" last="Cohen">Henri Cohen</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Psychology and Cognitive Neuroscience Laboratory, Université Paris Descartes - CNRS (UMR-8189)</s1><s2>Boulogne-Billancourt</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Boulogne-Billancourt</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0131705</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0131705 INIST</idno><idno type="RBID">Pascal:10-0131705</idno><idno type="wicri:Area/PascalFrancis/Corpus">000604</idno><idno type="wicri:Area/PascalFrancis/Curation">000D53</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000520</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000520</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Affect in Parkinson's disease: validation of the two-factor approach</title><author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Psychology and Cognitive Neuroscience Laboratory, Université Paris Descartes - CNRS (UMR-8189)</s1><s2>Boulogne-Billancourt</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Boulogne-Billancourt</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre de Recherche Université Laval Robert-Giffard</s1><s2>Beauport</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Centre de Recherche Université Laval Robert-Giffard</wicri:noRegion></affiliation></author><author><name sortKey="Remillard, Sophie" sort="Remillard, Sophie" uniqKey="Remillard S" first="Sophie" last="Remillard">Sophie Remillard</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Cohen, Henri" sort="Cohen, Henri" uniqKey="Cohen H" first="Henri" last="Cohen">Henri Cohen</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Psychology and Cognitive Neuroscience Laboratory, Université Paris Descartes - CNRS (UMR-8189)</s1><s2>Boulogne-Billancourt</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Boulogne-Billancourt</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Journal of the neurological sciences</title><title level="j" type="abbreviated">J. neurol. sci.</title><idno type="ISSN">0022-510X</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of the neurological sciences</title><title level="j" type="abbreviated">J. neurol. sci.</title><idno type="ISSN">0022-510X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Depression</term><term>Depression Inventory Beck</term><term>Hyperkinesia</term><term>Idiopathic</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Placebo</term><term>Surgical approach</term><term>Validation</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Etat dépressif</term><term>Hyperkinésie</term><term>Pathologie du système nerveux</term><term>Validation</term><term>Voie abord</term><term>Idiopathique</term><term>Placebo</term><term>Depression Inventory Beck</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Depression in Idiopathic Parkinson's disease (IPD) is frequent, difficult to recognize, under managed and has a profound impact on quality of life. Current categorization of diagnosis in psychiatry poorly applies to the protean manifestations of mood disorders presented by parkinsonian patients. In this study we have chosen to dissect the state of depressive mood as assessed with the Beck Depression Inventory (BDI) at different points in time of pharmacological interventions using a dimensional approach. The 21 items of the BDI were classified in two new categories or factors: hyperkinetic and hypokinefic. The hyperkinetic factor included all items related to unbalanced intrusions of negative feelings and ideas, as well as to behavioral hyperactivity. The hypokinetic factor included all items related to loss of drive for appetitive behaviors and loss of mental and physical energy. The objectives were to (1) compare different pharmacological treatments on the two-factor approach in PD depression, (2) determine the influence of levodopa therapy on the two-factor approach, and (3) explore the two-factor approach in placebo conditions. Three sets of analyses using the hypo/hyperkinetic dichotomy favour a neurobiological dissociation of these factors in response to pharmacological intervention: symptoms of the hyperkinetic factor are responsive to serotonergic drugs while those of the hypokinetic one are not and may even show deterioration under SSRIs. In contrast, the hypokinetic factor is responsive to dopaminergic drugs and may show deterioration under serotonergic drugs. Furthermore, the two factors seem to transiently dissociate on placebo intervention aiming at correcting either mood or motor status. The dimensional approach to depression symptomatology may thus be of heuristic value in probing aminergic modulation of mood in IPD and establishing new correlations between affective and motor symptoms.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-510X</s0></fA01><fA02 i1="01"><s0>JNSCAG</s0></fA02><fA03 i2="1"><s0>J. neurol. sci.</s0></fA03><fA05><s2>289</s2></fA05><fA06><s2>1-2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Affect in Parkinson's disease: validation of the two-factor approach</s1></fA08><fA09 i1="01" i2="1" l="ENG"><s1>Mental Dysfunction in Parkinson's Disease: Proceedings of the 9<sup>th</sup> International Congress on Mental Dysfunction and other Non-Motor Features in Parkinson's Disease and Related Disorders, Dresden, Germany, 16-19 October 2008</s1></fA09><fA11 i1="01" i2="1"><s1>POURCHER (Emmanuelle)</s1></fA11><fA11 i1="02" i2="1"><s1>REMILLARD (Sophie)</s1></fA11><fA11 i1="03" i2="1"><s1>COHEN (Henri)</s1></fA11><fA12 i1="01" i2="1"><s1>REICHMANN (Heinz)</s1><s9>ed.</s9></fA12><fA12 i1="02" i2="1"><s1>KORCZYN (Amos D.)</s1><s9>ed.</s9></fA12><fA14 i1="01"><s1>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="02"><s1>Psychology and Cognitive Neuroscience Laboratory, Université Paris Descartes - CNRS (UMR-8189)</s1><s2>Boulogne-Billancourt</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="03"><s1>Centre de Recherche Université Laval Robert-Giffard</s1><s2>Beauport</s2><s3>CAN</s3><sZ>1 aut.</sZ></fA14><fA15 i1="01"><s1>Department of Neurology, Dresden University Medical School</s1><s2>Dresden</s2><s3>DEU</s3><sZ>1 aut.</sZ></fA15><fA15 i1="02"><s1>Department of Neurology, Tel Aviv University Medical School</s1><s2>Ramat Aviv</s2><s3>ISR</s3><sZ>2 aut.</sZ></fA15><fA20><s1>27-31</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>12185</s2><s5>354000190042590060</s5></fA43><fA44><s0>0000</s0><s1>© 2010 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>18 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>10-0131705</s0></fA47><fA60><s1>P</s1><s2>C</s2></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of the neurological sciences</s0></fA64><fA66 i1="01"><s0>IRL</s0></fA66><fC01 i1="01" l="ENG"><s0>Depression in Idiopathic Parkinson's disease (IPD) is frequent, difficult to recognize, under managed and has a profound impact on quality of life. Current categorization of diagnosis in psychiatry poorly applies to the protean manifestations of mood disorders presented by parkinsonian patients. In this study we have chosen to dissect the state of depressive mood as assessed with the Beck Depression Inventory (BDI) at different points in time of pharmacological interventions using a dimensional approach. The 21 items of the BDI were classified in two new categories or factors: hyperkinetic and hypokinefic. The hyperkinetic factor included all items related to unbalanced intrusions of negative feelings and ideas, as well as to behavioral hyperactivity. The hypokinetic factor included all items related to loss of drive for appetitive behaviors and loss of mental and physical energy. The objectives were to (1) compare different pharmacological treatments on the two-factor approach in PD depression, (2) determine the influence of levodopa therapy on the two-factor approach, and (3) explore the two-factor approach in placebo conditions. Three sets of analyses using the hypo/hyperkinetic dichotomy favour a neurobiological dissociation of these factors in response to pharmacological intervention: symptoms of the hyperkinetic factor are responsive to serotonergic drugs while those of the hypokinetic one are not and may even show deterioration under SSRIs. In contrast, the hypokinetic factor is responsive to dopaminergic drugs and may show deterioration under serotonergic drugs. Furthermore, the two factors seem to transiently dissociate on placebo intervention aiming at correcting either mood or motor status. The dimensional approach to depression symptomatology may thus be of heuristic value in probing aminergic modulation of mood in IPD and establishing new correlations between affective and motor symptoms.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Etat dépressif</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Depression</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Estado depresivo</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Hyperkinésie</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Hyperkinesia</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Hiperquinesia</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Validation</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Validation</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Validación</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Voie abord</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Surgical approach</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Vía abordaje</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Idiopathique</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Idiopathic</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Idiopático</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Placebo</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Placebo</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Placebo</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Depression Inventory Beck</s0><s2>NP</s2><s5>13</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Depression Inventory Beck</s0><s2>NP</s2><s5>13</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Depression Inventory Beck</s0><s2>NP</s2><s5>13</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Trouble de l'humeur</s0><s5>42</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Mood disorder</s0><s5>42</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Trastorno humor</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0><s5>43</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0><s5>43</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Trouble de la psychomotricité</s0><s5>44</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Psychomotor disorder</s0><s5>44</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Trastorno psicomotriz</s0><s5>44</s5></fC07><fN21><s1>081</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA><pR><fA30 i1="01" i2="1" l="ENG"><s1>International Congress on Mental Dysfunction and other non-motor features in Parkinson's Disease and Related Disorders</s1><s2>9</s2><s3>Dresden DEU</s3><s4>2008-10-16</s4></fA30></pR></standard></inist><affiliations><list><country><li>Canada</li><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Boulogne-Billancourt</li></settlement></list><tree><country name="Canada"><noRegion><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name></noRegion><name sortKey="Cohen, Henri" sort="Cohen, Henri" uniqKey="Cohen H" first="Henri" last="Cohen">Henri Cohen</name><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name><name sortKey="Remillard, Sophie" sort="Remillard, Sophie" uniqKey="Remillard S" first="Sophie" last="Remillard">Sophie Remillard</name></country><country name="France"><region name="Île-de-France"><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name></region><name sortKey="Cohen, Henri" sort="Cohen, Henri" uniqKey="Cohen H" first="Henri" last="Cohen">Henri Cohen</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000520 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000520 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:10-0131705
|texte= Affect in Parkinson's disease: validation of the two-factor approach
}}
| This area was generated with Dilib version V0.6.29. |  |